Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%.
Excluding the sale of rights for Baqsimi, non-incretin revenue increased 17% worldwide and 25% in the U.S. Q2 2024 EPS increased 68% to $3.
28 on a reported basis and increased 86% to $3.92 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.
2024 full-year revenue guidance raised by $3 billion ; reported EPS guidance raised $2.05 to the range of $15.10 to $15.
60 , and non-GAAP EPS guidance raised $2.60 to the range of $16.10 to $16.
60 . Pipeline progress included approval of Kisunla in the U.S.
for Alzheimer's disease and Jaypirca in Japan for relapsed or refractory mantle cell lymphoma. Additional progress included submission of tirzepatide in the U.S.
and EU for obstructive sleep apnea and obesity, and positive topline results from the Phase 3 trial evaluating tirzepatide for heart failure with preserved ejection fraction and obesity. INDIANAPOLIS , Aug. 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the second quarter of 2024.
"Mounjaro, Zepbound and Verzenio led our strong financial performance in the second quarter as we advanced our manufacturing expansion agenda, and it is equally exciting to see the growth around the world of our medicines for cancer, neurological disorders and autoimmune diseases," .